RichterstetterMWullichBAmannKet al. The value of extended transurethral resesection of bladder tumor (TURBT) in the treatment of bladder cancer. BJU Int2012;110 (2Pt 2):e76-9.
2.
SylvesterRJvan der MeijdenAPOosterlinckWet al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol2006; 49:466-77.
3.
HerrHWDonatSM.Quality control in transurethral resection of bladder tumours. BJU Int2008; 102:1242-6.
4.
WuYPLinTTChenSHet al. Comparison of the efficacy and feasibility of en bloc transurethral resection of bladder tumor versus conventional transurethral resection. of bladder tumor A meta-analysis. Medicine (Baltimore)2016; 95:e5372.
5.
NaselliAPuppoP.En bloc transurethral resection of bladder tumors: a new standard?J Endourol2017;31(S1):S20-S24.
6.
NaselliAHurleRPaparellaSet al. Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus2017, Epub ahead of print.
7.
SylvesterRJOosterlinckWvan der MeijdenAP.A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol2004;171:2186-90.
8.
SylvesterRJOosterlinckWHolmangSet al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation?Eur Urol2016;69:231-44.
9.
AbernMROwusuRAAndersonMRRampersaudENInmanBA. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. J Natl Compr Canc Netw2013;11:477-84.
10.
PerlisNZlottaARBeyeneJFinelliAFleshnerNEKulkarniGS. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non–muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol2013;64:421-30.
11.
BurksFNLiuABSuhRSet al. Understanding the use of immediate intravesical chemotherapy for patients with bladder cancer. J Urol2012;188(6):2108-13.
12.
CambierSSylvesterRJColletteLet al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol2016;69:60-9.
13.
ShelleyMDKynastonHCourtJet al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int2001;88:209-16.
14.
BohleAJochamDBockPR.Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol2003;169:90-5.
15.
ShelleyMDWiltTJCourtJColesBKynastonHMasonMD. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int2004;93:485-90.
16.
HanRFPanJG.Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology2006;67:1216-23.
17.
MalmstromPUSylvesterRJCrawfordDEet al. An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol2009;56:247-56.
18.
BrausiMOddensJSylvesterRet al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomized phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol2014;65:69-76.
19.
HerrHW.Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria. J Urol. 2012;187(2):435-7.
